GlassScriptPhysician profile
Trenton Cleghern
NPI 1083090815
$3,391.20
in general payments reported to CMS, 2019-2025
27 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $933 · 2020: $399 · 2021: $179 · 2022: $842 · 2023: $569 · 2024: $355 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,037.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,037.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $534.58 | 2019-2020 | |
| Alcon Vision LLC | $337.49 | 2019-2024 | Rocklatan |
| Sun Pharmaceutical Industries INC. | $295.00 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $259.18 | 2023-2024 | Xiidra, Miebo, Vyzulta |
| Oyster Point Pharma, INC. | $219.84 | 2022-2023 | Tyrvaya |
| Biotissue Holdings INC. | $218.70 | 2019-2023 | |
| Allergan, INC. | $197.92 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $197.51 | 2019-2022 | |
| Abbvie INC. | $179.12 | 2022-2025 | |
| Eyevance Pharmaceuticals LLC | $161.34 | 2022 | |
| Glaukos Corporation | $134.92 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $121.82 | 2024 | Xdemvy |
| Alexion Pharmaceuticals, INC. | $103.56 | 2022-2025 | Soliris, Ultomiris |
| Mallinckrodt Hospital Products INC. | $80.28 | 2020-2021 | |
| Derma Sciences, INC. | $57.71 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $55.67 | 2022 | |
| Aerie Pharmaceuticals, INC. | $34.96 | 2019-2021 | |
| Argenx US, INC. | $31.69 | 2023 | Vyvgart |
| Thea Pharma INC. | $28.87 | 2022-2023 | |
| Dompe US, INC. | $25.92 | 2025 | Oxervate |
| Coherus Oncology, INC. | $19.02 | 2022 | |
| Ani Pharmaceuticals, INC. | $18.10 | 2025 | Iluvien |
| Ivantis, INC | $17.60 | 2019 | |
| Rxsight INC | $17.56 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.50 | 2019 | |
| Shire North American Group INC | $13.55 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trenton Cleghern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.